Your browser doesn't support javascript.
Description of 3 patients with myasthenia gravis and COVID-19.
Rein, Netaniel; Haham, Nitzan; Orenbuch-Harroch, Efrat; Romain, Marc; Argov, Zohar; Vaknin-Dembinsky, Adi; Gotkine, Marc.
  • Rein N; Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: Netaniel.rein@mail.huji.ac.il.
  • Haham N; Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: Nitan.haham@mail.huji.ac.il.
  • Orenbuch-Harroch E; Hadassah-Hebrew University Medical Center, Medical intensive care unit, Jerusalem, Israel.
  • Romain M; Hadassah-Hebrew University Medical Center, Medical intensive care unit, Jerusalem, Israel. Electronic address: Marcro@hadassah.org.il.
  • Argov Z; Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: zohara@ekmd.huji.ac.il.
  • Vaknin-Dembinsky A; Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel.
  • Gotkine M; Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: marc@gotkine.com.
J Neurol Sci ; 417: 117053, 2020 10 15.
Artículo en Inglés | MEDLINE | ID: covidwho-665223
ABSTRACT

BACKGROUND:

The COVID-19 pandemic presents two main concerns for patients with myasthenia gravis (MG); chronic immunosuppression may put them at greater risk, and some proposed treatments for COVID-19 could cause MG exacerbation. CASE DESCRIPTION We present three patients with generalized seropositive MG who developed COVID-19. All patients had a favorable outcome, with only one patient experiencing exacerbation. In this case, exacerbation began before COVID-19; she required ICU admission, non-invasive ventilatory support, and received hydroxychloroquine, lopinavir and ritonavir which were well tolerated. One patient received IVIG in place of scheduled plasma exchange.

CONCLUSION:

Outcome was favorable in all cases despite immunosuppressive therapy, use of experimental COVID-19 medication and switching of plasma exchange for IVIG.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Neumonía Viral / Infecciones por Coronavirus / Pandemias / Betacoronavirus / Miastenia Gravis Tipo de estudio: Reporte de caso / Estudio pronóstico Tópicos: Covid persistente Límite: Adulto / Anciano / Femenino / Humanos / Masculino Idioma: Inglés Revista: J Neurol Sci Año: 2020 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Neumonía Viral / Infecciones por Coronavirus / Pandemias / Betacoronavirus / Miastenia Gravis Tipo de estudio: Reporte de caso / Estudio pronóstico Tópicos: Covid persistente Límite: Adulto / Anciano / Femenino / Humanos / Masculino Idioma: Inglés Revista: J Neurol Sci Año: 2020 Tipo del documento: Artículo